Gilead
NASDAQ:GILDPharmaFoster City, California, United States · Est. 1987 · 17,000 employees
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing medicines in virology, oncology, and inflammation.
38
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
38
Indications↗
Distinct diseases across all programs
755
Clinical Trials↗
All sponsored trials (all statuses)
59
Orange Book Patents
Across 7 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
38 drugs in development
Approved1
Phase 320
Phase 29
Phase 113
Preclinical7
By Therapeutic Area
top 5
Infectious Disease
1835%
Oncology
1325%
Immunology
612%
Gastroenterology
12%
Neurology
12%
R&D Momentum
81/100
Pipeline Velocity
39/100
Trial Completion Rate
76/100
Pipeline Concentration
26/100
Pipeline Freshness
64/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Terminated
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Sep 19, 2026
Completed
A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout
Sep 19, 2026
Completed
A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
Sep 19, 2026
Terminated
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection
Sep 19, 2026
Completed
Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
Sep 18, 2026
Active, not recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Sep 16, 2026
Recruiting
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Sep 16, 2026
Recruiting
Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)
Sep 12, 2026
Active, not recruiting
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Sep 12, 2026
Active, not recruiting
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Sep 10, 2026
Recruiting
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Sep 10, 2026
Recruiting
An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1
Details
Company Info
Company Overview
$100.0B
Mkt Cap
$22.1B
Revenue
$5.3B
Cash
CEODaniel O'Day
Founded1987
Employees17,000
HQFoster City, California, United States
ExchangeNASDAQ:GILD
Websitegilead.com
LinkedInCompany Page
Therapeutic Focus
ImmunologyOncologyInfectious DiseaseGastroenterologyOtherRare DiseaseNephrologyCardiovascularMusculoskeletalMetabolic & EndocrineNeurologyPsychiatry
Recent SEC Filings
8-KAug 4, 2026
FORM 8-K
EX-99.1Feb 10, 2026
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology(1 drug)
—
—
—
1
—
Gastroenterology(1 drug)
Immunology(6 drugs)
—
4
1
1
—
Immunology(6 drugs)
Infectious Disease(18 drugs)
2
1
2
13
1
Infectious Disease(18 drugs)
Neurology(1 drug)
—
1
—
—
—
Neurology(1 drug)
Oncology(13 drugs)
3
7
4
3
—
Oncology(13 drugs)
Unknown / Other(13 drugs)
2
2
4
9
1
Unknown / Other(13 drugs)
Regulatory
Regulatory Timeline
20202 events
FDAOct 22
Veklury — VEKLURY
Application NDA214787 (NDA)
FDAAug 27
Sovaldi — SOVALDI
Application NDA204671
20224 events
FDADec 22
Sunlenca — SUNLENCA
Application NDA215973 (NDA)
FDADec 22
Sunlenca — SUNLENCA
Application NDA215974 (NDA)
FDADec 22
Sunlenca — SUNLENCA
Application NDA215973
FDADec 22
Sunlenca — SUNLENCA
Application NDA215974
20248 events
FDADec 23
Sovaldi — SOVALDI
Application NDA212480
FDADec 23
Sovaldi — SOVALDI
Application NDA204671
FDANov 25
Sunlenca — SUNLENCA
Application NDA215973
FDANov 25
Sunlenca — SUNLENCA
Application NDA215974
FDANov 13
Sunlenca — SUNLENCA
Application NDA215974
FDANov 13
Sunlenca — SUNLENCA
Application NDA215973
FDAJul 17
Sunlenca — SUNLENCA
Application NDA215973
FDAJul 17
Sunlenca — SUNLENCA
Application NDA215974
20253 events
FDAJun 20
Tybost — TYBOST
Application NDA203094 (NDA)
FDAJun 18
Sunlenca — YEZTUGO
Application NDA220020 (NDA)
FDAJun 18
Sunlenca — YEZTUGO
Application NDA220018 (NDA)
20265 events
SECAug 4
FORM 8-K
Accession: 0000882095-26-000028
FDAMay 22
HEPCLUDEX — HEPCLUDEX
Application BLA761468 (BLA)
FDAMar 12
Sunlenca — SUNLENCA
Application NDA215973
FDAMar 12
Sunlenca — SUNLENCA
Application NDA215974
SECFeb 10
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Accession: 000-19731
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)